/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Entera Bio Ltd

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$2.05 -0.0721(-7.21%) ENTX at 04 Dec 2025 04:30 PM Biotechnology
Lowest Today 2.06
Highest Today 2.25
Today’s Open 2.25
Prev. Close 2.22
52 Week High 3.22
52 Week Low 1.50
Day’s Range: Low 2.06 High 2.25
52-Week Range: Low 1.50 High 3.22
1 day return -
1 Week return -13.58
1 month return -25.26
3 month return -3.22
6 month return -
1 year return +17.31
3 year return +200.0
5 year return +87.5
10 year return -

Institutional Holdings

Knoll Capital Management LP 12.88

Point72 Asset Management, L.P. 5.91

Schonfeld Strategic Advisors LLC 1.32

Parkman Healthcare Partners LLC 0.78

Northern Trust Corp 0.44

Bessemer Group Inc 0.31

HighTower Advisors, LLC 0.15

Renaissance Technologies Corp 0.14

Susquehanna International Group, LLP 0.11

Signature Estate & Investment Advisors 0.10

Bank of America Corp 0.05

Fidelity Nasdaq Composite Index 0.05

Geode Capital Management, LLC 0.05

UBS Group AG 0.03

Citadel Advisors Llc 0.03

Jane Street Group LLC 0.02

PNC Financial Services Group Inc 0.02

Goss Wealth Management LLC 0.02

Cubist Systematic Strategies, LLC 0.00

Group One Trading, LP 0.00

Perigon Wealth Management, LLC 0.00

Market Status

Strong Buy: 0

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 101.80 M

PB Ratio 6.8933

PE Ratio 0.0

Enterprise Value 96.65 M

Total Assets 9.39 M

Volume 123398

Company Financials

Annual Revenue FY23:14000 0.0M, FY22:134000 0.1M, FY21:571000 0.6M, FY20:365000 0.4M, FY19:236000 0.2M

Annual Profit FY23:6000 0.0M, FY22:33000 0.0M, FY21:198000 0.2M, FY20:156000 0.2M, FY19:26000 0.0M

Annual Net worth FY23:-9929000 -9.9M, FY22:-13071000 -13.1M, FY21:-12187000 -12.2M, FY20:-9983000 -10.0M, FY19:-10879000 -10.9M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:42000 0.0M, Q3/2024:42000 0.0M, Q2/2024:57000 0.1M

Quarterly Profit Q3/2025:-8000 -0.0M, Q2/2025:-7000 -0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:9000 0.0M

Quarterly Net worth Q3/2025:-3200000 -3.2M, Q2/2025:-2656000 -2.7M, Q1/2025:-2567000 -2.6M, Q3/2024:-3021000 -3.0M, Q2/2024:-2145000 -2.1M

Fund house & investment objective

Company Information Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial for the treatment of post-menopausal women with low bone mineral density and high-risk osteoporosis; and has completed Phase 1 clinical trial to treat stress fractures. In addition, the company is developing EB612, a tablet peptide replacement therapy for hypoparathyroidism. Further, it develops oral oxyntomodulin (OXM), a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity and metabolic disorders; and GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions, such as short bowel syndrome. The company has research collaboration agreement with OPKO Biologics, Inc. Entera Bio Ltd. was incorporated in 2009 and is headquartered in Jerusalem, Israel.

Organisation Biotechnology

Employees 20

Industry Biotechnology

CEO Ms. Miranda J. Toledano M.B.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow